Parkinson’s therapy mirivadelgat selected for multi-drug clinical trial
Foresee Pharmaceuticals’ oral therapy mirivadelgat has been selected to enter the Phase 2a SLEIPNIR platform trial, which is testing several experimental treatments for Parkinson’s disease. The trial,…